Month: June 2021

TORONTO, CHICAGO and MONTREAL, June 10, 2021 (GLOBE NEWSWIRE) — Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) today announced that it has expanded its medical affairs team in preparation for the planned launch of treosulfan, a bifunctional alkylating agent, in the United States. Treosulfan is an innovative, orphan-designated agent developed for use as part of a conditioning treatment for patients undergoing allogeneic hematopoietic stem cell transplantation (“allo-HSCT”). With more than 100 publications supporting its safety and efficacy, management believes treosulfan is ideally positioned to become the new standard of care in the U.S. As such, pro-actively putting in place the right people and resources ahead of the scheduled Prescription Drug User Fee Act (“PDUFA”) date,...

Patient enrollment to begin in early second half of 2021 in U.K. and Canada GeneTx to submit revised protocol to U.S. Food and Drug Administration seeking study resumption in U.S. following May meeting SARASOTA, Fla. and NOVATO, Calif., June 10, 2021 (GLOBE NEWSWIRE) — GeneTx Biotherapeutics LLC and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), companies partnered in the development of intrathecally administered GTX-102, an investigational treatment for Angelman syndrome, today announced that the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the Clinical Trial Application (CTA) for the Phase 1/2 study of GTX-102 in pediatric patients with Angelman syndrome in the U.K. The companies previously received clearance to enroll patients in the Phase 1/2 study in Canada. The first patients from these regions...

WALTHAM, Mass., June 10, 2021 (GLOBE NEWSWIRE) — Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will participate in the virtual JMP Securities Life Sciences Conference on June 16, 2021 at 10:00 a.m. Eastern Time. The presentation will be webcast and accessible on a live and archived basis through the investor relations section of the Company’s web site, http://ir.minervaneurosciences.com. About Minerva Neurosciences Minerva’s portfolio of compounds includes: roluperidone (MIN-101), in clinical development for schizophrenia, and MIN-301, in pre-clinical development for Parkinson’s disease. Minerva’s common stock is listed on the NASDAQ Global Market under the symbol “NERV.” For...

– Data indicate that berdazimer sodium prevents progression of SARS-CoV-2 infection in two independent in vivo transmission studies – – Statistically significant, dose-dependent reduction in the amount of virus in the lung with doses as low as 2 mg/mL – – Preliminary toxicology and pharmacology study results suggest intranasal administration is well-tolerated and safe – DURHAM, N.C., June 10, 2021 (GLOBE NEWSWIRE) — Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced positive preclinical results with berdazimer sodium in a SARS-CoV-2 transmission model in golden Syrian hamsters. In light of these promising results, the Company is exploring opportunities to develop an anti-viral therapy against COVID-19, the disease caused by the SARS-CoV-2 virus, both internally and potentially through strategic partnerships...

PSYC’s Industry Leading media platform, Psychedelic Spotlight, Shines in May LAKE OSWEGO,OR, June 10, 2021 (GLOBE NEWSWIRE) — Global Trac Solutions, Inc. (OTCPink: PSYC) (“Global” “PSYC” or the “Company”) the first publicly traded digital media company within the emerging sector of medicinal psychedelics, is pleased to announce that its Psychedelic Spotlight media platform received nearly 125K page views in the month of May setting yet another record high for the platform which had previously hit 105K page views in the month of April. The Company contends that this encouraging data, observed from Google Analytics, demonstrates the growing audience and following it continues to amass within the emerging sector of medicinal psychedelics, and more specifically, at a time when the industry itself continues to garner more attention...

BERKELEY HEIGHTS, N.J., June 10, 2021 (GLOBE NEWSWIRE) — CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it has completed the sale of $1.3 million of its available tax benefits to an unrelated, profitable New Jersey corporation through the New Jersey Economic Development Authority’s New Jersey Technology Business Tax Certificate Transfer program for the State Fiscal Year 2020. As a result, the Company has received approximately $1.3 million in cash proceeds from the sale of these NOL tax benefits. The New Jersey Technology Business Tax Certificate Transfer (NOL) program enables qualified, unprofitable NJ-based technology or biotechnology companied with fewer than...

DENVER, June 10, 2021 (GLOBE NEWSWIRE) — Assure Holdings Corp. (the “Company” or “Assure”) (TSXV: IOM; OTCQB: ARHH), a provider of intraoperative neuromonitoring services (“IONM”), is pleased to announce that it has entered into a definitive agreement (the “Agreement”) with Centurion Financial Trust, an investment trust formed by Centurion Asset Management Inc. (“Centurion”) in respect of an US$11,000,000 credit facility comprised of a US$6,000,000 senior term loan (the “Senior Term Loan”), a US$2,000,000 senior revolving loan (the “Senior Revolving Loan”) and a US$3,000,000 senior term acquisition line (the “Senior Term Acquisition Line” and together with the Senior Term Loan and the Senior Revolving Loan, the “Credit Facility”). ”We have capitalized on the recent momentum in our business to further strengthen our balance sheet...

SCOTTSDALE, Ariz., June 10, 2021 (GLOBE NEWSWIRE) — AgJunction Inc. (TSX: AJX) and its wholly-owned subsidiary, Novariant, Inc. (together “AgJunction” or the “Company”), today announced that it has reached an agreement in principle to settle the patent infringement and breach of contract lawsuit it filed against Ag Leader Technology, Inc. in November of 2020. The parties will work diligently to finalize a settlement agreement and related documents in the coming weeks. In the event they are not able to reach a final agreement, the parties will resume litigation in court. About AgJunction AgJunction Inc. is a global leader of advanced guidance and autosteering solutions for precision agriculture applications. Its technologies are critical components in over 30 of the world’s leading precision Ag manufacturers...

CALGARY, Alberta, June 10, 2021 (GLOBE NEWSWIRE) — CEMATRIX Corporation (TSXV: CVX) (OTCQB: CTXXF) (“CEMATRIX” or the “Company“) a North American leading manufacturer and supplier of technologically advanced cellular concrete products announced that its wholly owned operating subsidiaries, which include CEMATRIX (Canada) Inc. (“CCI”), MixOnSite USA Inc. (“MOS”) and Pacific International Grout Company (“PIGCO’) have executed $8.1 million in contracts, the majority of which were converted from contracts in process. Factoring in the $6.6M in converted and new contracts and sales completed to date, the Corporation’s backlog now totals $94.0 million. $21.3 million of the Corporation’s backlog is now Contracted and $72.7 million is Contracts in Process. As of January 1, 2021, the Corporation’s Backlog is defined...

NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, June 10, 2021 (GLOBE NEWSWIRE) — Thesis Gold Inc. (TSXV: TAU) (WKN: A2QQ0Y) (“Thesis” or the “Company“) is pleased to announce today the pricing of its previously announced overnight marketed offering (the “Offering”) and an increase to the size of the Offering to up to $16,000,000 from $12,000,000 due to investor demand by key investors. The Offering will now be for gross proceeds of up to $10,000,000 for common shares of the Company (the “Non-Flow Through Shares”) at a price of $1.50 per Non-Flow Through Share for the issuance of up to 6,666,666 Non-Flow Through Shares and gross proceeds of up to $6,000,000 for common shares of the Company which qualify as “flow-through...